What is the recommended post‑exposure prophylaxis for chickenpox (varicella) in healthy non‑immune individuals and in those who cannot receive a live‑attenuated varicella vaccine (e.g., immunocompromised, pregnant, newborn, infant <12 months, or severe chronic illness)?

Post-Exposure Prophylaxis for Chickenpox

For healthy non-immune individuals, administer varicella vaccine within 3 days of exposure (up to 5 days is acceptable); for those who cannot receive live vaccine (immunocompromised, pregnant, newborns at risk, infants <12 months), administer VariZIG as soon as possible and within 10 days of exposure. 1

Healthy Non-Immune Individuals

Varicella Vaccine as Post-Exposure Prophylaxis

• Administer varicella vaccine within 3 days of exposure for >90% effectiveness in preventing disease 1
• Vaccination within 5 days of exposure provides approximately 70% effectiveness in preventing varicella and 100% effectiveness in modifying severe disease 1
• This applies to all unvaccinated persons without other evidence of immunity, including adults 1

Key Implementation Points

• If exposure does not result in infection, post-exposure vaccination provides protection against future exposures 1
• Consider administering a second dose to individuals who previously received only one dose to bring them up-to-date, though specific efficacy data for this scenario are limited 1
• No evidence suggests that administering vaccine during the presymptomatic or prodromal stage increases adverse events 1
• Recent outbreak data from 2018 confirms vaccination remains effective even when given >5 days post-exposure, though earlier administration is superior 2

High-Risk Individuals Who Cannot Receive Live Vaccine

VariZIG (Varicella Zoster Immune Globulin) Administration

Timing is critical: Administer VariZIG as soon as possible after exposure and within 10 days 1

• The FDA-approved window was extended from 96 hours to 10 days based on international data showing comparable disease attenuation 1
• Earlier administration (within 4 days) may be slightly more effective, but administration up to 10 days still provides meaningful protection 1

Specific High-Risk Groups Requiring VariZIG

VariZIG is indicated for the following populations without evidence of immunity: 1

• Immunocompromised patients (including those on steroid therapy >2 mg/kg body weight or >20 mg/day prednisone equivalent) 1
• Pregnant women without evidence of immunity 1
• Newborn infants whose mothers develop varicella 5 days before to 2 days after delivery 1
• Hospitalized premature infants ≥28 weeks gestation whose mothers lack immunity to varicella 1
• Hospitalized premature infants <28 weeks gestation or ≤1,000 g birth weight, regardless of maternal immunity 1

VariZIG Dosing

• Dose: 125 IU per 10 kg body weight, maximum 625 IU (five vials) 1
• Minimum dose: 62.5 IU (0.5 vial) for patients ≤2.0 kg 1
• Minimum dose: 125 IU (one vial) for patients 2.1-10.0 kg 1
• Administered intramuscularly 1

Critical Monitoring and Follow-Up

Post-VariZIG Management

• Monitor patients for 28 days after exposure (extended from the typical 21-day incubation period, as VariZIG may prolong incubation by ≥1 week) 1
• Institute antiviral therapy immediately if signs or symptoms of varicella develop 1
• For patients receiving monthly high-dose IVIG (>400 mg/kg), VariZIG is likely unnecessary if IVIG was given <3 weeks before exposure 1
• If re-exposure occurs ≥3 weeks after initial VariZIG dose, administer another full dose 1

Vaccination After VariZIG

• Delay varicella vaccination for ≥5 months after VariZIG administration to avoid interference with vaccine response 1

Alternative Prophylaxis Considerations

Antiviral Prophylaxis

• While acyclovir is sometimes used as post-exposure prophylaxis, recent 2024 data from 47 children's hospitals showed acyclovir was associated with the highest rate of subsequent varicella disease (15.4%) compared to VariZIG (3.4%) 3
• A 2022 study suggested acyclovir/valacyclovir can be effective in immunocompromised children, but this contradicts the larger 2024 dataset 4
• Acyclovir prophylaxis should be considered only when VariZIG is unavailable or contraindicated, not as a first-line alternative 3

Common Pitfalls to Avoid

• Do not delay VariZIG administration waiting for serologic confirmation of immunity status in high-risk patients with significant exposure 1
• Do not use MMRV vaccine for post-exposure prophylaxis—no data support its use in this setting; use single-antigen varicella vaccine 1
• Do not assume bone marrow transplant recipients are immune based on pre-transplant history; they should be considered non-immune regardless of donor or recipient history 1
• Do not administer VariZIG to patients who received 2 doses of varicella vaccine before becoming immunocompromised; instead, monitor closely and treat with acyclovir if disease develops 1

Contraindications to VariZIG

• History of anaphylactic or severe systemic reactions to human immune globulins 1
• IgA-deficient patients with antibodies against IgA and history of hypersensitivity 1